This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-08 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
The only prediction that can be made is statistical and expresses an average rate of decay. This rate can be represented by adjusting the curve of a decaying exponential distribution with a decay constant (λ) particular to the isotope. On this understanding the radioactive decay of an initial population of unstable atoms over time t follows the curve given by e−λt. One of the most important properties of any radioactive material follows from this analysis, its half-life. This refers to the time required for half of a given number of radioactive atoms to decay and is inversely related to the isotope's decay constant, λ. Half-lives have been determined in laboratories for many radionuclides, and can range from nearly instantaneous—hydrogen-5 decays in less time than it takes for a photon to go from one end of its nucleus to the other—to fourteen orders of magnitude longer than the age of the universe: tellurium-128 has a half-life of 2.2×1024 years.
Established changes to the bone structure of the face are also unaffected by HRT. A significant majority of craniofacial changes occur during adolescence. Post-adolescent growth is considerably slower and minimal by comparison. Facial hair develops during puberty and is only slightly affected by HRT. A person's voice is unaffected by feminizing hormone therapy. Transgender individuals who have undergone male puberty often opt for vocal training, which can take years of practice to achieve the desired results. Some may also opt for vocal surgery, though surgeons recommend this in addition to vocal training, not as an alternative.
Bromley Picturehouse was opened in June 2019 in the previous Empire theatre. The cinema closed on 1 August 2024. Vue Cinemas own a nine-screen cinema, which is part of the Bromley South Central scheme at St Mark's Square, opened on 28 November 2018.
== Career == At the start of his career in 1980, Tanzi worked as a research technologist for James Gusella at Massachusetts General Hospital. There, he assisted in localizing the Huntington's disease gene; their findings were published in Nature in 1983. This was the first study to localize a disease gene purely based on genetic linkage with genomic variants. In 1987, based on his doctoral studies at Harvard Medical School, he was the lead author of seven papers published in Science and Nature between 1987 and 1988, describing the initial cloning, mapping, and characterization of the gene encoding the amyloid beta-protein precursor (APP), the first reported Alzheimer’s disease gene. Two other groups reported the cloning of APP at that time. In 1991-1992, Tanzi and Wilma Wasco, discovered the two APP family members, APLP1 and APLP2. In 1995, Tanzi collaborated with Drs. Peter Hyslop and Jerry Schellenberg to discover the two other EO-FAD genes, presenilin 1 and 2 (PSEN1 and PSEN2). He has published many key studies characterizing the role of the EO-FAD genes in health and disease. All three genes remain among the most highly studied drug targets in the field of AD aimed at reducing beta-amyloid deposition. In 1993, Tanzi first discovered the gene for the neurodegenerative disease, Wilson's disease; his findings were published in Nature Genetics. In that same year, he contributed to the discovery of the first familial amyotrophic lateral sclerosis (ALS) gene, SOD1, by providing the key genetic and physical mapping data for chromosome 21 used to find the gene defect.
The Lord Ramage series by Dudley Pope takes place during the Napoleonic Wars. Jeanette Winterson's 1987 novel The Passion. Georgette Heyer's 1937 novel An Infamous Army recounts the fortunes of a family in the run-up to and during the course of, the Battle of Waterloo. Heyer's novel is noted for its meticulous research on the progress of the battle, combining her noted period romance writing with her detailed research into regency history. The Battle (French: La Bataille) is a historical novel by the French author Patrick Rambaud that was first published in 1997 and again in English in 2000. The book describes the 1809 Battle of Aspern-Essling between the French Empire under Napoleon and the Austrian Empire. The novel was awarded the Prix Goncourt and the Grand Prix du roman de l'Académie française for 1997. In Jasper Kent's novel Twelve, 1812 Russian Invasion serves as a base story for the book. In later books from The Danilov Quintet, this war is constantly mentioned. The Fighting Sail series by Alaric Bond portrays life and action aboard Royal Naval vessels during the Revolutionary and Napoleonic Wars. From the lower decks to the quarterdeck Bond's detailed settings are realistic. Narratives are told not just from a commissioned officer's point of view but include varied perspectives, including warranted officers, ordinary and able seamen, marines, supernumeraries, and women aboard presenting a broader, more complete picture of the Georgian Navy.
Sources: en.wikipedia.org
== Prognosis == The early stages of AD are difficult to diagnose. A definitive diagnosis is usually made once cognitive impairment compromises daily living activities, although the person may still be living independently. The symptoms will progress from mild cognitive problems, such as memory loss, through increasing stages of cognitive and non-cognitive disturbances, eliminating any possibility of independent living, especially in the late stages of the disease. Life expectancy of people with AD is reduced. The normal life expectancy for 60 to 70-year-olds is 23 to 15 years; for 90-year-olds, it is 4.5 years. Following AD diagnosis it ranges from 7 to 10 years for those in their 60s and early 70s (a loss of 13 to 8 years), to only about 3 years or less (a loss of 1.5 years) for those in their 90s. As of 1995, fewer than 3% of people lived more than fourteen years after diagnosis. Disease features significantly associated with reduced survival are increased severity of cognitive impairment, decreased functional level, disturbances in the neurological examination, history of falls, malnutrition, dehydration and weight loss. Other coincident diseases such as heart problems, diabetes, or history of alcohol abuse are also related with shortened survival. While the earlier the age at onset the higher the total survival years, life expectancy is particularly reduced when compared to the healthy population among those who are younger. Men have a less favorable survival prognosis than women, even after controlling for age and some medical conditions.
== Sources == Flegel, Melinda J. (2004). Sport first aid: A coach's guide to preventing and responding to injuries. Hong Kong, Japan: Human Kinetics. Lindsay, R., Watson, G., Hickmont, D., Broadfoot, A., & Bruynel, L. (1994). Treat your own strains sprains and bruises. New Zealand: Spinal Publications. Lovering, R.M. (2008). "Physical therapy and related interventions". In P.M. Tiidus (ed.), Skeletal muscle damage and repair (pp. 219–230). United States of America: Human Kinetics. Prentice, William E. "Tissue Response to Injury", Principles of Athletic Training: A Competency Based Approach. 14th ed. New York: McGraw Hill Companies, 2011. 260–277. Subotnick, Steven (1991). Sports and Exercise Injuries: Conventional, Homeopathic and Alternative Treatments. California, United States of America: North Atlantic Books.
=== China === In 2024, China’s supreme court and chief prosecutor jointly issued the Interpretation of Several Issues Concerning the Application of Law in Handling Criminal Cases of Money Laundering (2024). In American and British English, this title would translate to Money Laundering Prosecution Guidelines, and they explain how Criminal Law act section 191 applies to money laundering proceeds from specific unlawful activities. The guidelines treat money laundering done for concealment of criminal proceeds as a section 191 criminal offense both when tied to the offender’s own unlawful activity and when tied to unlawful activity committed by others, and directs courts to assess whether a defendant met a knowledge or reason-to-know standard based on totality-of-the-circumstances factors. The guidelines also identify aggravating circumstances where at least 5,000,000 yuan is laundered with specified sentencing enhancements, sets mandatory minimum fine amounts of 10,000 yuan for sentences up to five years imprisonment or jail and 200,000 yuan for sentences of five to ten years, superseding prior guidance from 2009 money laundering adjudicative guidelines. It is regulated by the China Anti-Money Laundering Monitoring and Analysis Center
=== Chemical industry === Stainless-steel belts are part of continuous production processes. Unlike conveyor belts used purely for transportation purposes, steel belts used in this industry serve as media for transferring heat and/or pressure. Applications for steel belts in the chemical industry include casting, polymerizing of resins, waxes, paraffins and many other substances.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.